Mazdutide

Mazdutide (IBI362 / LY3305677) is a synthetic peptide dual agonist of the GLP-1 and glucagon receptors developed by Innovent Biologics under license from Eli Lilly. The compound is in late-stage clinical development in China for type 2 diabetes and obesity.

Peppudex card: see the mechanism + evidence-grade summary at [Peppudex / Mazdutide](https://peppudex.com/peptides/mazdutide).

Overview

Mazdutide is structurally related to oxyntomodulin, the endogenous gut hormone with dual GLP-1 / glucagon receptor activity. The peptide is engineered for once-weekly subcutaneous administration with extended half-life from albumin binding.

Mechanism

Mazdutide binds and activates both the GLP-1 and glucagon receptors. The GLP-1 arm drives satiety, slowed gastric emptying, and glucose-dependent insulin secretion; the glucagon arm increases hepatic lipolysis and energy expenditure. The combination drives weight loss through both reduced intake and increased expenditure.

See: GLP-1_receptor, Glucagon_receptor, Incretin_effect.

Evidence

Clinical evidence in Chinese populations:

• Phase 2 obesity · 24-week trial in 248 Chinese adults with obesity reported placebo-subtracted weight loss of approximately 11.1% at 9 mg weekly (Ji et al., JAMA Netw Open 2024).
• Phase 3 GLORY-1 · 48-week Phase 3 trial in Chinese adults with obesity, primary endpoint met (NMPA review 2024-2025).
• Phase 2 type 2 diabetes · HbA1c reduction in Chinese adults with T2D.

Dosing literature

Phase 2 and 3 trials titrated subcutaneous doses from 3 mg to 9 mg once weekly. The wiki does not recommend any human dose; mazdutide is investigational outside China and not FDA-approved.

Pharmacokinetics

Mazdutide carries a fatty-acid linker for albumin binding with terminal half-life of approximately 5 to 6 days, supporting once-weekly subcutaneous dosing. Pharmacokinetic profile is broadly similar to other once-weekly incretin agonists in the same generation (tirzepatide, retatrutide, survodutide). Steady state reached after 4 to 5 weeks.

Storage

Lyophilized mazdutide is stable at –20 °C for at least 24 months. After reconstitution with bacteriostatic water, store at 2-8 °C and use within 28 days.

Regulatory status

• China. NDA submitted to NMPA for obesity (2024); review ongoing.
• United States. Investigational. Not FDA-approved.
• WADA. Not listed on the 2024 Prohibited List.

Side effects (per published Phase 2 + 3)

Adverse-event profile across the Chinese Phase 2 and Phase 3 trials is dominated by gastrointestinal events (nausea, vomiting, diarrhea, decreased appetite), consistent with the GLP-1/GCGR dual mechanism. Discontinuation rates due to AEs are concentrated in the titration period. The glucagon-receptor arm produces modest dose-dependent heart-rate increases similar to other dual GLP-1/glucagon agonists.

See also

• Semaglutide · GLP-1 mono-agonist comparator
• Tirzepatide · GLP-1/GIP dual agonist
• Survodutide · GLP-1/glucagon dual agonist (BI)
• Retatrutide · GLP-1/GIP/glucagon triple agonist
• [Peppudex card · Mazdutide](https://peppudex.com/peptides/mazdutide) · mechanism, evidence grades A-F, FAQs, peer-reviewed sources

References

• Ji L, et al. "Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial." Diabetes Care. 2024.
• Zhao H, et al. "Mazdutide (IBI362) in obese Chinese adults: dose-finding phase 2 study." JAMA Netw Open. 2024.